TAO Synergies (TAOX) Interest & Investment Income (2019 - 2026)
TAO Synergies' (TAOX) quarterly Interest & Investment Income came in at $25255.0 in Q2 2026, down 83.47% on a YoY basis from $152798.0 in Q2 2025, and down 28.82% quarter-over-quarter from $35479.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Interest & Investment Income (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Interest & Investment Income for 8 consecutive years, with $25255.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income fell 83.47% year-over-year to $25255.0; the trailing twelve-month figure through Jun 2026 stood at $168515.0 (down 79.38% YoY), and the FY2025 full-year result was $442913.0, down 65.29% from the prior year.
- Interest & Investment Income eased to $25255.0 in Q2 2026 per TAOX's latest filing, from $35479.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $549995.0 in Q3 2023 and bottomed at $4610.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $209084.5 across 5 years, with a median of $167049.5 in 2024.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income surged 8497.77% in 2023, then plunged 85.6% in 2025.
- Over 5 years, Interest & Investment Income stood at $145212.0 in 2022, then jumped by 89.68% to $275439.0 in 2023, then slumped by 34.18% to $181301.0 in 2024, then tumbled by 64.43% to $64489.0 in 2025, then slumped by 60.84% to $25255.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $25255.0, $35479.0, and $64489.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | 36.92 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 25,255.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25,255.00 |
| Mar 31, 2026 | 35,479.00 |
| Dec 31, 2025 | 64,489.00 |
| Sep 30, 2025 | 43,292.00 |
| Jun 30, 2025 | 152,798.00 |
| Mar 31, 2025 | 182,334.00 |
| Dec 31, 2024 | 181,301.00 |
| Sep 30, 2024 | 300,681.00 |
| Jun 30, 2024 | 330,508.00 |
| Mar 31, 2024 | 463,395.00 |
| Dec 31, 2023 | 275,439.00 |
| Sep 30, 2023 | 549,995.00 |
| Jun 30, 2023 | 427,159.00 |
| Mar 31, 2023 | 396,357.00 |
| Dec 31, 2022 | 145,212.00 |
| Sep 30, 2022 | 140,730.00 |
| Jun 30, 2022 | 44,487.00 |
| Mar 31, 2022 | 4,610.00 |
| Dec 31, 2021 | 2,518.00 |
| Sep 30, 2021 | 2,445.00 |